Michiaki Kubo

86.1k citations

385 papers · 18.3k indexed · 2 hit papers · h-index 77

Molecular Biology top 1%
Genetics top 0.2%
Epidemiology top 0.5%
Surgery top 1%
Oncology top 1%

Co-authors: Atsushi Takahashi Yutaka Kiyohara Mitsuo Iida Naoyuki Kamatani Yusuke Nakamura Koichi Matsuda Naoya Hosono Yoichiro Kamatani
Topics: Genetic Associations and Epidemiology (64 papers)Liver Disease Diagnosis and Treatment (26 papers)Estrogen and related hormone effects (20 papers)
Cited by: Nephrology Genetics Cancer Research
Journals: Nature Circulation Nature Medicine
Partner nations: Japan United States Italy

In The Last Decade

Michiaki Kubo

380 papers receiving 17.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases

2018 413 citations Masahiro Kanai, Masato Akiyama et al. profile →
Comprehensive evaluation of structural variation detection algorithms for whole genome sequencing

2019 278 citations Yukihide Momozawa, Chikashi Terao et al. profile →

Peers

Countries citing papers authored by Michiaki Kubo

Since Specialization

Citations

This map shows the geographic impact of Michiaki Kubo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michiaki Kubo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michiaki Kubo more than expected).

Fields of papers citing papers by Michiaki Kubo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michiaki Kubo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michiaki Kubo. The network helps show where Michiaki Kubo may publish in the future.

Co-authorship network of co-authors of Michiaki Kubo

This figure shows the co-authorship network connecting the top 25 collaborators of Michiaki Kubo. A scholar is included among the top collaborators of Michiaki Kubo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michiaki Kubo. Michiaki Kubo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance) 2024 ·The Pharmacogenomics Journal ·Jai N. Patel,Chen Jiang,Kouros Owzar,Daniel L. Hertz,Janey Wang,Flora Mulkey,William Kevin Kelly,Susan Halabi,Yoichi Furukawa,(unknown),Susan G. Dorsey,Paula N. Friedman,Eric J. Small,Michael A. Carducci,Michael J. Kelley,Yusuke Nakamura,Michiaki Kubo,Mark J. Ratain,Michael J. Morris,Howard L. McLeod	0
2	Genome-wide association study reveals BET1L associated with survival time in the 137,693 Japanese individuals 2023 ·Communications Biology ·Masato Akiyama,Saori Sakaue,Atsushi Takahashi,Kazuyoshi Ishigaki,Makoto Hirata,Koichi Matsuda,Yukihide Momozawa,Yukinori Okada,Toshiharu Ninomiya,(unknown),Masaru Koido,Takayuki Morisaki,Akiko Nagai,Yoji Sagiya,Chikashi Terao,Yoshinori Murakami,Michiaki Kubo,Yoichiro Kamatani	2
3	The high-dimensional space of human diseases built from diagnosis records and mapped to genetic loci 2023 ·Nature Computational Science ·(unknown),Yu Li,Xue Zhong,Kanix Wang,Milton Pividori,(unknown),(unknown),Hatem Ltaief,Chikashi Terao,Masato Akiyama,Koichi Matsuda,David E. Keyes,Hae Kyung Im,Takashi Gojobori,Yoichiro Kamatani,Michiaki Kubo,Nancy J. Cox,James A. Evans,Xin Gao,Andrey Rzhetsky	4
4	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance) 2020 ·Clinical Cancer Research ·Federico Innocenti,Alexander B. Sibley,(unknown),Amy S. Etheridge,Chen Jiang,Fang‐Shu Ou,(unknown),Sarah J. Plummer,Graham Casey,Monica M. Bertagnolli,Howard L. McLeod,J. Todd Auman,Charles D. Blanke,Yoichi Furukawa,Alan P. Venook,Michiaki Kubo,Heinz‐Josef Lenz,Joel S. Parker,Mark J. Ratain,Kouros Owzar	13
5	Variants encoding a restricted carboxy-terminal domain of SLC12A2 cause hereditary hearing loss in humans 2020 ·PLoS Genetics ·Hideki Mutai,Koichiro Wasano,Yukihide Momozawa,Yoichiro Kamatani,Fuyuki Miya,Sawako Masuda,Noriko Morimoto,Kiyomitsu Nara,Satoe Takahashi,Tatsuhiko Tsunoda,Kazuaki Homma,Michiaki Kubo,Tatsuo Matsunaga	40
6	Deep whole-genome sequencing reveals recent selection signatures linked to evolution and disease risk of Japanese 2018 ·Nature Communications ·Yukinori Okada,Yukihide Momozawa,Saori Sakaue,Masahiro Kanai,Kazuyoshi Ishigaki,Masato Akiyama,Toshihiro Kishikawa,Yasumichi Arai,Takashi Sasaki,Kenjiro Kosaki,Makoto Suematsu,Koichi Matsuda,Kazuhiko Yamamoto,Michiaki Kubo,Nobuyoshi Hirose,Yoichiro Kamatani	84
7	Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer 2018 ·Cancer Medicine ·Daniel Shepshelovich,Amanda Townsend,Osvaldo Espin‐Garcia,Lidija Latifovic,Chris J. O’Callaghan,Derek J. Jonker,Dongsheng Tu,Eric X. Chen,Eric Morgen,Timothy Price,Jeremy Shapiro,Lillian L. Siu,Michiaki Kubo,Alexander Dobrovic,Mark J. Ratain,Wei Xu,Taisei Mushiroda,Geoffrey Liu	20
8	Genome-wide association analysis of common genetic variants of resistant hypertension 2018 ·The Pharmacogenomics Journal ·(unknown),Nihal El Rouby,Caitrin W. McDonough,Yan Gong,Leslie A. McClure,Braxton D. Mitchell,Richard B. Horenstein,Robert L. Talbert,Dana C. Crawford,Matthew A. Gitzendanner,Atsushi Takahashi,Toshihiro Tanaka,Michiaki Kubo,Carl J. Pepine,Rhonda M. Cooper‐DeHoff,Oscar Benavente,Alan R. Shuldiner,Julie A. Johnson	16
9	Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer 2017 ·Clinical Cancer Research ·M. Eileen Dolan,(unknown),Heather E. Wheeler,Eric R. Gamazon,Shirin Ardeshir‐Rouhani‐Fard,Patrick O. Monahan,Darren R. Feldman,Robert J. Hamilton,David J. Vaughn,Clair J. Beard,Chunkit Fung,Jeri Kim,Sophie D. Fosså,Daniel L. Hertz,Taisei Mushiroda,Michiaki Kubo,Lawrence H. Einhorn,Nancy J. Cox,Lois B. Travis	63
10	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes 2017 ·npj Breast Cancer ·Duan Liu,Ming‐Fen Ho,Daniel J. Schaid,Steven E. Scherer,Krishna R. Kalari,Mohan Liu,Joanna M. Biernacka,Vivien C. Yee,Jared M. Evans,Erin E. Carlson,Matthew P. Goetz,Michiaki Kubo,D. Lawrence Wickerham,Liewei Wang,James N. Ingle,Richard M. Weinshilboum	11
11	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy 2016 ·Cancer Research ·James N. Ingle,Fang Xie,Matthew J. Ellis,Paul E. Goss,Lois E. Shepherd,J. W. Chapman,Bingshu E. Chen,Michiaki Kubo,Yoichi Furukawa,Yukihide Momozawa,Vered Stearns,Kathleen I. Pritchard,Poulami Barman,Erin E. Carlson,Matthew P. Goetz,Richard M. Weinshilboum,Krishna R. Kalari,Liewei Wang	43
12	ALDH2 polymorphism is associated with fasting blood glucose through alcohol consumption in Japanese men. 2016 ·PubMed ·Guang Yin,Mariko Naito,Kenji Wakai,M. Emi,Sayo Kawai,Nobuyuki Hamajima,Sadao Suzuki,Yoshikuni Kita,Toshiro Takezaki,Keitaro Tanaka,Makiko Morita,Hirokazu Uemura,Etsuko Ozaki,Satoyo Hosono,Haruo Mikami,Michiaki Kubo,Hideo Tanaka	11
13	Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy 2015 ·Clinical Cancer Research ·Masaaki Komatsu,Heather E. Wheeler,Suyoun Chung,Siew‐Kee Low,Claudia Wing,Shannon M. Delaney,Lidija K. Gorsic,Atsushi Takahashi,Michiaki Kubo,Deanna L. Kroetz,Wei Zhang,Yusuke Nakamura,M. Eileen Dolan	36
14	A Rare Polymorphic Variant of NBS1 Reduces DNA Repair Activity and Elevates Chromosomal Instability 2014 ·Cancer Research ·Yuki Yamamoto,Mamiko Miyamoto,(unknown),Michiaki Kubo,Hitoshi Nakagama,Yusuke Nakamura,Hitoshi Satoh,Koichi Matsuda,Toshiki Watanabe,Tsutomu Ohta	8
15	Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention 2013 ·Cancer Discovery ·James N. Ingle,Mohan Liu,D. Lawrence Wickerham,Daniel J. Schaid,Liewei Wang,Taisei Mushiroda,Michiaki Kubo,Joseph P. Costantino,Victor G. Vogel,Soonmyung Paik,Matthew P. Goetz,Matthew M. Ames,Gregory D. Jenkins,Anthony Batzler,Erin E. Carlson,David A. Flockhart,Norman Wolmark,Yusuke Nakamura,Richard M. Weinshilboum	56
16	Correction: Genome Wide Association Study of Age at Menarche in the Japanese Population 2013 ·PLoS ONE ·Chizu Tanikawa,Yukinori Okada,Atsushi Takahashi,Katsutoshi Oda,Naoyuki Kamatani,Michiaki Kubo,Yusuke Nakamura,Koichi Matsuda	12
17	Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy 2012 ·Clinical Cancer Research ·Heather E. Wheeler,Eric R. Gamazon,Claudia Wing,(unknown),(unknown),R. Michael Baldwin,Kouros Owzar,Chen Jiang,Dorothy Watson,Ivo Shterev,Michiaki Kubo,Hitoshi Zembutsu,Eric P. Winer,Clifford A. Hudis,Lawrence N. Shulman,Yusuke Nakamura,Mark J. Ratain,Deanna L. Kroetz,Nancy J. Cox,(unknown)	49
18	A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 2012 ·Clinical Cancer Research ·R. Michael Baldwin,Kouros Owzar,Hitoshi Zembutsu,Aparna Chhibber,Michiaki Kubo,Chen Jiang,Dorothy Watson,(unknown),Joel Mefford,Howard L. McLeod,Paula N. Friedman,Clifford A. Hudis,Eric P. Winer,Eric Jorgenson,John S. Witte,Lawrence N. Shulman,Yusuke Nakamura,Mark J. Ratain,Deanna L. Kroetz	160
19	Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics 2012 ·The Pharmacogenomics Journal ·Yuan Ji,(unknown),Scott J. Hebbring,Yubo Chai,G. Douglas Jenkins,(unknown),Karen Snyder,Maureen S. Drews,Zeruesenay Desta,David A. Flockhart,Taisei Mushiroda,Michiaki Kubo,Yoshimasa Nakamura,Naoyuki Kamatani,Daniel J. Schaid,Richard M. Weinshilboum,David A. Mrazek	52
20	Common Variants in a Novel Gene, FONG on Chromosome 2q33.1 Confer Risk of Osteoporosis in Japanese 2011 ·PLoS ONE ·Ikuyo Kou,Atsushi Takahashi,Tomohiko Urano,Naoshi Fukui,Hideki Ito,Kouichi Ozaki,Toshihiro Tanaka,Takayuki Hosoi,Masataka Shiraki,Satoshi Inoue,Yusuke Nakamura,Naoyuki Kamatani,Michiaki Kubo,Seijiro Mori,Shiro Ikegawa	31

About Michiaki Kubo

Michiaki Kubo is a scholar working on Genetics, Cancer Research and Nephrology, having authored 385 papers that have together received 18.3k indexed citations. Recurring topics across this work include Genetic Associations and Epidemiology (64 papers), Liver Disease Diagnosis and Treatment (26 papers) and Estrogen and related hormone effects (20 papers). The work is most often cited by research in Nephrology (1.2k citations), Genetics (4.3k citations) and Cancer Research (2.0k citations). Michiaki Kubo has collaborated with scholars based in Japan, United States and Italy. Frequent co-authors include Atsushi Takahashi, Yutaka Kiyohara, Mitsuo Iida, Naoyuki Kamatani, Yusuke Nakamura, Koichi Matsuda, Naoya Hosono, Yoichiro Kamatani, Yumihiro Tanizaki and Toshiharu Ninomiya. Their work appears in journals such as Nature, Circulation and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact